Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial

Inclusion Criteria:

• Informed consent obtained before any trial-related activity
• Completed the full treatment period of the extension trial EASE SBS 2 (ZP1848-17127)

Exclusion Criteria:

• Any condition, disease, or circumstance that in the Investigator's opinion would putthe patient at any undue risk, prevent completion of the trial, or confound theplanned assessments of the trial
• Not having a colonoscopy performed at End of Trial in EASE SBS 2 (for patients withremnant colon). Note. The results of the colonoscopy must not give rise to any safetyconcerns. A colonoscopy performed within 6 months prior to End of Trial and not givingrise to any safety concerns is accepted. For patients with a remnant colon, which isnot connected to the passage of foods and is thereby dormant, a computerizedtomography (CT) scan or magnetic resonance imaging (MRI) will suffice at thediscretion of the Investigator
• Use of GLP-1, GLP-2, human growth hormone (HGH), dipeptidyl peptidase-4 (DPP-4)inhibitors, somatostatin, or analogs thereof within 3 months. Note: Prior use ofglepaglutide trial drug is allowed
• Females of childbearing potential, who are pregnant, breast-feeding, intend to becomepregnant, or are not using highly effective contraceptive methods